Taysha IPO Presentation Deck

Also developing a common approach to treat Lafora and APBD, with potential to treat other GSDs In Lafora disease and APBD, glycogen chain elongation outpaces glycogen branching Elongated glycogen molecules accumulate into toxic polyglucosan bodies Downregulation of glycogen synthase (GYS) can prevent polyglucosan body formation Taysha is pursuing a GYS-miRNA therapy for the treatment of Lafora and APBD The estimated prevalence of GSDs is 20,000 patients in the US and EU AAV9 IDATI GYS-miRNA Intrathecal delivery Hippocampal PB quantification (% area) N AM Ç Ma H Gbefy Gyst Gyenge Spa Activity | Gyst GYS-miRNA REDUCTION IN POLYGLUCOSAN Gys1 deficiency results In reduction of polyglucosan bodies 56

View entire presentation